|Bid||5,114.00 x 200|
|Ask||5,119.00 x 34100|
|Day's Range||5,110.00 - 5,175.00|
|52 Week Range||51.41 - 5,175.00|
|PE Ratio (TTM)||-837.43|
|Forward Dividend & Yield||1.36 (7.11%)|
|1y Target Est||N/A|
Shares of several large generic drugmakers fell in Wednesday midday trade. Mylan NV shares dropped 2.7%, Teva Pharmaceutical Industries Ltd. shares dropped 2.1% , Taro Pharmaceutical Industries Ltd. shares ...
The deal comes at a time when speedy approvals of generics by U.S. regulators have ratcheted up competition in the sector, mounting pressure on smaller drugmakers such as Impax, which has a market cap of about $1.48 billion (£1.1 billion). Adding to the woes of generics makers, U.S. retail pharmacies including Wal-Mart Stores Inc (WMT.N) and Walgreens Boots Alliance Inc (WBA.O) are wielding more leverage when buying such drugs, leading to continued price erosion.
Kare Schultz will start his new post as chief executive of Israel's Teva Pharmaceutical Industries by the end of October, the Calcalist financial newspaper reported on Tuesday. A Teva spokesman, asked about the Israeli news report, said the company does not comment on market rumours. Teva poached Schultz from Denmark's Lundbeck in September, handing the drugs industry veteran the urgent task of convincing investors of the struggling Israeli firm's future.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for fremanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibody for the preventive treatment of migraine. TEVA Chief Scientific Officer Michael Hayden commented, "The BLA submission for fremanezumab marks a very important milestone for the migraine community [...] There have been few therapeutic innovations for migraine patients in over 25 years. If approved, fremanezumab will be among the first to enter the market in a new class of drugs for the preventive treatment of migraine.
BDSI further said that additional terms of the settlement agreement are confidential and that the agreement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice. A Teva spokeswoman confirmed the settlement agreement and launch date.
Categories: Europe Value Analsysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Teva Pharmaceutical Industries Ltd. a score of 75. Our analysis is based on comparing Teva Pharmaceutical Industries Ltd. with the following peers – Compugen Ltd. and XTL Biopharmaceuticals Ltd. (CGEN-IL and XTLB-IL). Investment Outlook Teva Pharmaceutical Industries Ltd. has a fundamental score of 75 and has a ... Read more (Read more...)
Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Teva Pharmaceutical Industries Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
With another challenge cropping up for Teva (TEVA) in the form of earlier-than-expected generic competition for the 40 mg dose of Copaxone, here is a look at 5 drug stocks that look better-positioned.
BT Group PLC (BT), Cardinal Health Inc. (CAH), Teva Pharmaceutical Industries Ltd (TEVA), and Chipotle Mexican Grill Inc. (CMG) have declined to their respective three-year lows.
Teva's blockbuster multiple sclerosis treatment Copaxone will face additional generic competition in Europe, just two days after Mylan NV won U.S. approval to sell cheaper versions of the medicine in the world's largest market. Mylan's European partner, Synthon, and Alvogen said on Thursday they had received decentralized European approval for a 40 milligram dose of glatiramer acetate, as Copaxone is known generically. Nearly 20 percent of total sales for Teva Pharmaceutical Industries comes from branded Copaxone.
Teva's blockbuster multiple sclerosis treatment Copaxone faces more generic competition in Europe, just two days after regulators approved cut-price copies of the medicine in the United States. Privately held Alvogen and Synthon said on Thursday they had received decentralised European approval for a 40 mg dose of glatiramer acetate, as Copaxone is known generically. Copaxone is Teva's best-selling drug, generating more than $4 billion in revenue for the Israeli drugmaker last year.
Teva's (TEVA) shares plunged after Mylan announced an earlier-than-expected launch of its generic version of the 40-mg thrice-weekly formulation of its blockbuster multiple sclerosis drug, Copaxone.
The multiple sclerosis drug Copaxone brought in $4 billion last year for Teva, and generic competition wasn’t expected until at least 2018.
A surprise move from the Food and Drug Administration means that a recovery for Teva Pharmaceutical Industries just got much more difficult.